Bruijnzeel Adrie W
Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, 32610, USA.
Brain Res Rev. 2009 Dec 11;62(1):127-46. doi: 10.1016/j.brainresrev.2009.09.008. Epub 2009 Oct 2.
The dynorphin-like peptides have profound effects on the state of the brain reward system and human and animal behavior. The dynorphin-like peptides affect locomotor activity, food intake, sexual behavior, anxiety-like behavior, and drug intake. Stimulation of kappa-opioid receptors, the endogenous receptor for the dynorphin-like peptides, inhibits dopamine release in the striatum (nucleus accumbens and caudate putamen) and induces a negative mood state in humans and animals. The administration of drugs of abuse increases the release of dopamine in the striatum and mediates the concomitant release of dynorphin-like peptides in this brain region. The reviewed studies suggest that chronic drug intake leads to an upregulation of the brain dynorphin system in the striatum and in particular in the dorsal part of the striatum/caudate putamen. This might inhibit drug-induced dopamine release and provide protection against the neurotoxic effects of high dopamine levels. After the discontinuation of chronic drug intake these neuroadaptations remain unopposed which has been suggested to contribute to the negative emotional state associated with drug withdrawal and increased drug intake. kappa-Opioid receptor agonists have also been shown to inhibit calcium channels. Calcium channel inhibitors have antidepressant-like effects and inhibit the release of norepinephrine. This might explain that in some studies kappa-opioid receptor agonists attenuate nicotine and opioid withdrawal symptomatology. A better understanding of the role of dynorphins in the regulation of brain reward function might contribute to the development of novel treatments for mood disorders and other disorders that stem from a dysregulation of the brain reward system.
强啡肽样肽对大脑奖赏系统的状态以及人类和动物行为有着深远影响。强啡肽样肽会影响运动活性、食物摄入、性行为、焦虑样行为和药物摄入。刺激κ-阿片受体(强啡肽样肽的内源性受体)会抑制纹状体(伏隔核和尾状壳核)中的多巴胺释放,并在人类和动物中诱发负面情绪状态。滥用药物会增加纹状体中多巴胺的释放,并介导该脑区中强啡肽样肽的伴随释放。所综述的研究表明,长期药物摄入会导致纹状体尤其是纹状体/尾状壳核背侧部分的脑强啡肽系统上调。这可能会抑制药物诱导的多巴胺释放,并提供针对高多巴胺水平神经毒性作用的保护。在长期药物摄入停止后,这些神经适应性变化未受到抑制,这被认为是导致与药物戒断相关的负面情绪状态和药物摄入量增加的原因。κ-阿片受体激动剂也已被证明可抑制钙通道。钙通道抑制剂具有类抗抑郁作用,并抑制去甲肾上腺素的释放。这可能解释了在一些研究中κ-阿片受体激动剂可减轻尼古丁和阿片类药物戒断症状。更好地理解强啡肽在调节大脑奖赏功能中的作用可能有助于开发针对情绪障碍和其他源于大脑奖赏系统失调的疾病的新疗法。